Division of Hematology-Oncology, Milton S. Hershey Cancer Institute, Penn State University, Hershey, PA.
Department of Pathology, Milton S. Hershey Cancer Institute, Penn State University, Hershey, PA.
Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):e515-e519. doi: 10.1016/j.clml.2018.06.028. Epub 2018 Jul 4.
Multiple myeloma (MM) is characterized by the secretion of monoclonal protein by malignant plasma cells in the vast majority of cases. We identified and analyzed patterns of disease relapse and progression associated with disappearance of the paraprotein ("nonsecretory [NS] escape"), or conversion from production of intact Ig molecule to its associated light chain ("LC escape").
We retrospectively reviewed medical records and a database of 791 consecutive patients with symptomatic MM.
Twenty-eight (3.5%) patients had disease evolution associated with either NS (n = 13) or LC (n = 15) escape. The event occurred at a median of 37 months (range, 3-156 months) after the diagnosis of MM, and after a median of 3 chemotherapy regimens (range, 1-8 regimens). Presence of extramedullary disease at progression was detected in 8 (29%) patients. Sensitivity to chemotherapy before and after escape was present in 21 (75%) and 14 (50%) patients, respectively. After a median follow-up of 55 months, 19 (68%) patients died, and progressive MM was the cause of death in 18 patients. The median overall survival after escape was 20 months (95% confidence interval, 9-25 months), and no significant difference was found between the NS and LC groups (P = .44). The median overall survival after diagnosis of MM was worse in patients with NS/LC escape than in those without escape (52 vs. 94 months; P = .018).
Our study describes the largest series of NS and LC escape in MM to date. The development of this phenomenon is associated with more aggressive clinical features, frequent resistance to chemotherapy, and worse clinical outcome.
多发性骨髓瘤(MM)的特征是绝大多数情况下恶性浆细胞分泌单克隆蛋白。我们发现并分析了与异常蛋白(“非分泌性[NS]逃逸”)消失相关的疾病复发和进展模式,或从完整 Ig 分子的产生转变为其相关的轻链(“LC 逃逸”)。
我们回顾性地审查了 791 例有症状 MM 连续患者的病历和数据库。
28 例(3.5%)患者的疾病进展与 NS(n=13)或 LC(n=15)逃逸有关。该事件发生在 MM 诊断后中位数为 37 个月(范围 3-156 个月),中位数接受了 3 种化疗方案(范围 1-8 种方案)。在 8 例(29%)进展患者中检测到骨髓外疾病。逃逸前后对化疗的敏感性分别为 21 例(75%)和 14 例(50%)。中位随访 55 个月后,19 例(68%)患者死亡,18 例患者死于进展性 MM。逃逸后中位总生存期为 20 个月(95%置信区间,9-25 个月),NS 和 LC 组之间无显著差异(P=0.44)。与无逃逸患者相比,有 NS/LC 逃逸患者的 MM 诊断后总生存期更差(52 个月 vs. 94 个月;P=0.018)。
我们的研究描述了迄今为止 MM 中最大的 NS 和 LC 逃逸系列。这种现象的发展与更具侵袭性的临床特征、频繁的化疗耐药性以及更差的临床结局相关。